Precocious alteration of digestive enzyme activities in small intestine and pancreas by chronic oral administration of protease inhibitor in suckling rats.
1. The role of endogenous CCK in the development of digestive enzyme activities in small intestine and pancreas was investigated in suckling rats. Synthetic protease inhibitor (camostat 100 micrograms/g bwt) was orally administered twice daily for 5 days from 11 days of age. 2. Pancreatic hypertrophy and hyperplasia, and alteration of pancreatic enzyme composition, especially decreases in amylase activity and increases in trypsin and chymotrypsin activities were produced by camostat treatment. These changes were completely suppressed by simultaneous administration of the potent CCK receptor antagonist L-364,718 (1 microgram/g bwt). 3. With camostat treatment, intestinal lactase activity decreased to 41%, while maltase and sucrase activities increased 3 and 2.5 times respectively. These changes in enzyme activities were not affected by the application of L-364,718. 4. The mucosal disaccharidase and pancreatic enzyme activities could not be modified by chronic subcutaneous injection of camostat. The precocious induction of maltase and sucrase activities by camostat treatment was also observed in the adrenalectomized pups. 5. These results indicate that pancreatic growth accompanied by alteration of digestive enzyme composition in the suckling rats is regulated by endogenous CCK, but the precocious induction of disaccharidase activities is not mediated by endogenous CCK released by camostat treatment.
Department of Physiology, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
E
E
Harada
B
B
Syuto
D000284:Administration, Oral; D000315:Adrenalectomy; D000818:Animals; D000831:Animals, Newborn; D001570:Benzodiazepinones; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D020109:Devazepide; D004063:Digestion / Q000502:physiology; D004952:Esters; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines; D007279:Injections, Subcutaneous; D007421:Intestine, Small / Q000201:enzymology*; D010179:Pancreas / Q000201:enzymology*; D011480:Protease Inhibitors; D051381:Rats; D011919:Rats, Inbred Strains; D011949:Receptors, Cholecystokinin / Q000502:physiology
D001570:Benzodiazepinones; D004952:Esters; D006146:Guanidines; D011480:Protease Inhibitors; D011949:Receptors, Cholecystokinin; C034532:camostat; D016670:Gabexate; D002766:Cholecystokinin; D020109:Devazepide